Ilizarov bone transport and treatment of critical-sized tibial bone defects: a narrative review

Kemal Aktuglu*, Kubilay Erol and Arman Vahabi

Abstract

Background: Critical-sized bone defects of the tibia are complex injuries associated with significant problems that are difficult to treat, and they are associated with a significant burden of disease in clinical practice; however, the treatment of these cases has still been a challenge for orthopedic surgeons. The aim of this review was to evaluate the current available studies reporting on classical Ilizarov methods in the treatment of infected or noninfected critical-sized bone defects of the tibia, and to perform an analysis of treatment period and complications.

Methods: This is a narrative review based on a comprehensive literature search among the studies in Pubmed, Scopus and Web of Science articles. The studies included were written in the English language or translated to English and they were published between 2008 and 2018. They were appraised with narrative data synthesis. The primary outcome measures were the external fixation time (EFT), bone union rate, and bone and functional results. Secondary outcomes were complications including docking site problems and solutions. The heterogeneity of the data in the studies which were taken into consideration allowed a narrative analysis.

Results: Twenty-seven articles with 619 patients were included in this study. These included 6 prospective and 21 retrospective case series. Mean age was 36.1 (range 13–89) years. Of the cases, 88.8% were infected and the remaining 11.2% were noninfected. The external fixation time was 10.75 (range 2.5–23.2) months. The mean bone union rate was 90.2% (range 77–100)%. Radiographic outcome measures were reported in 20 studies. Functional outcome measures were reported in 18 studies. ASAMI (Association for the Study of the Method of Ilizarov) criteria are useful and give reproducible data on patient outcome measurements. Data collected from these studies showed excellent radiological outcomes in 303, good in 143, fair in 31, and poor in 25 patients. Functional outcomes were excellent in 200, good in 167, fair in 58, and poor in 19, where reported. The excellent and good rate in bone results and functional results were 88.8% and 82.6%, respectively. The poor rate in bone results and functional results were 5% and 4.5%. Mean complication rate per patient was 1.22 (range 3–60). The most common complication was pin tract infection (PTI). Its occurrence was 46.6%. Joint stiffness followed PTI with a 25% incidence. The rates of refracture, malunion, infectious recurrence, and amputation, were 4%, 8.4%, 4.58%, and 1%, respectively.

Conclusions: This narrative review shows that the patients with infected or noninfected critical-sized tibial bone defects treated by Ilizarov methods had a low rate of poor bone and functional results. Therefore, Ilizarov methods may be a good choice for the treatment of infected or noninfected tibial bone defects. The small number of cases in some studies, the absence of homogeneity between studies and the fact that most data available are derived from retrospective studies are some of the difficulties encountered in the evaluation of evidence.

Level of evidence: V.

Keywords: Bone defect, Critical size, Ilizarov, Bone transport, Distraction osteogenesis

*Correspondence: kemal.aktuglu@gmail.com
Department of Orthopedics and Traumatology, Ege University, Talatpasa Bulvari, Sezik Apt., No: 61/3 Alsancak, Izmir, Turkey
Introduction

Infected or noninfected critical-sized tibial bone defects (CSBD) are common in clinical practice [1–3]; however, the treatment of these conditions has still been a challenge for orthopedic surgeons with even greater challenges in the presence of infection or associated soft tissue defects [4, 5]. There is not one standard definition of a critical-sized defect. CSBD are defined as those that will not heal spontaneously within a patient's lifetime [1, 2]. Several methods have been applied successfully in the treatment of infected or noninfected tibial CSBD, including bone grafting, free tissue transfer and antibiotic cement, but these treatments have obvious limitations, such as donor site morbidity, stress fracture, and restriction of the size of bone defects [2]. The primary contemporary means of reconstructing CSBD are the induced membranes technique, pioneered by Masquelet, and distraction osteogenesis (DO), introduced by Ilizarov. Both of these methods have modifications widely used today in large bone defects. In the last decade, the induced membrane technique, also known as the Masquelet technique, the classic Ilizarov method, and the modification of the Ilizarov bone transport method have gained popularity.

The Ilizarov method for the treatment of complex tibial pathology associated with CSBD generally involves bifenoc or trifocal bone transport. Bone transport is characterized by the gradual translocation of a segment of bone from a healthy area into a region of bone loss [4, 5]. Up to now, there have been numerous reports on the treatment of tibial bone defects by Ilizarov methods, and they have gradually become main treatments for infected tibial bone defects. Although bone defects treated by Ilizarov methods reached a satisfactory outcome in most studies, there were still some relatively unsatisfactory results in several studies [5, 6]. In addition, a relatively high rate of complication in Ilizarov methods has been reported in some clinical research [7, 8].

The systematic reviews and meta-analyses done before this field were mainly based on the evaluations of smaller series. The results obtained from this study should be evaluated along with the results of previous studies so that the place of classic Ilizarov treatment in infected or noninfected tibial bone defects can be understood better. In this narrative review, studies from the last 10 years, based on the traditional Ilizarov method, were taken into consideration. Although the number of Ilizarov-like cases is very high, due to many modifications made to the method we do not have homogenous studies to work on. In some studies, the traditional circular frame with a standard Ilizarov procedure is compared to hybrid and other types of fixators. Only classic Ilizarov related information was taken into consideration from these studies [4–6].

Historical aspect of distraction osteogenesis

The Ilizarov method, which is used in the treatment of complicated fractures of long bones, was first introduced in 1950 by Gavril Abramovich Ilizarov, in the Soviet Union. This revolutionary method for treating fractures, nonunions, deformities and other bone defects involved the use of a circular external fixator [7, 8]. In 1965, Russian high jump gold medalist Valery Brummell had a motorcycle accident that resulted in an injury on his right tibia. He had 29 operations and his leg remained in a cast for 3 years. The amputation of the leg was discussed, and his treatment was undertaken by Gavril Ilizarov. After his treatment, Brummell's leg was saved and he was able to jump again. Bone transport was the key to success in this treatment. Starting in the early 1950s, he worked in a village in Siberia, Kurgan, unknown to the rest of the world. After his success in treating Brummell, Ilizarov became known in Russia. Then, in 1982, he successfully treated a famous Italian explorer Carlo Mauri for a resistant nonunion of his tibia and it was only then that his principles were made known to the Western world [7–12].

Materials and methods

PubMed, Scopus and Web of Science databases were searched to identify articles published between January 2008 and December 2018 pertinent to the methods and outcomes of surgical treatment of CSBD by classic Ilizarov method. The standardized treatment included bacterial eradication by segmental resection, bone transport using an Ilizarov circular external fixator, and docking maneuver. The keywords used to identify relevant articles were ‘bone defect’ or ‘critical size(d)’, ‘bone transport’, ‘distraction osteogenesis’ and/or ‘large’, ‘tibia(l)’ and/or ‘Ilizarov’ (Fig. 1). With these keywords, 2711 articles were identified. In addition to those 2711 studies, 20 more studies from contacted authors were added. After removing duplicate studies, 1965 remained. Of these 1965, 1553 were excluded from the analysis because they failed to meet the surgical treatment criteria or to report postoperative outcomes, ineligible data type, ineligible study design, ineligible population or were case reports or series with fewer than 5 patients. There were 412 studies left for the first step of full text screening; 385 more studies were excluded in the full text review step, which failed to meet the above mentioned criteria.

If the information about the Ilizarov method was not clear enough, or insufficient, they were not considered as part of this report. The inclusion criteria for this study were as follows: the target population was patients with infected or noninfected CSBD; intervention methods were Ilizarov methods, including bone transport, the outcomes included were bone union; bone results and functional results were evaluated by ASAMI,
complications, EFT and EFI. Eligible studies included two above-mentioned outcomes, at least. Articles, excluding small case reports, and reviews written completely in English were considered. Duplicate or multiple publications of the same study were excluded. Studies involving pediatric series, non-traumatic bone defects, unilateral frame external fixator applications, lengthening over an intramedullary nail, free tissue transfer with distraction osteogenesis, animal models, basic research, abstracts, soft tissue repairs, and reports evaluating femoral and tibial bone defects together were excluded, and when it was impossible to extract or calculate the information about outcomes and/or surgical treatment of CSBD from the studies, these were eliminated. Patients were excluded from the study if they had neurological disorders affecting gait, or reported any systemic bone disease.

As a result, 27 studies and a total of 619 patients were eligible to be included in our analysis [13–39]. They fulfill the inclusion criteria, and data from these studies were reviewed. In this article, a study of cases where the traditional Ilizarov technique was used to treat infected or noninfected critical-sized tibial bone defects, published between 2008 and 2018 are presented. All relevant data that met the eligibility criteria were independently and separately extracted by three authors. Discrepancies were resolved by discussion with each other.

Results
Twenty-seven major studies published between 2008 and 2018 were identified in the literature that studied application of the Ilizarov technique on patients with large tibial bone defects. Twenty-one retrospective studies formed
the preponderance of the body of research. The remain-
der included 6 prospective cohorts [13, 18, 19, 22, 25, 33]. Out of the 27 studies, the treatment periods for the cases were not reported in 2 studies [20, 34]; the mean for the remaining 25 studies was 5 (range 1–19) years. The average number of cases in each study was 24 (range 7–86).

In 6 of the 27 studies, infected and noninfected CSBD were mixed [19, 25, 29–32, 39]. Eighteen studies included only infected tibial CSBD. When all 619 cases were taken into consideration, 535 of them were reported as infected bone defect, and 57 were reported as noninfected bone defect; the remaining 10 cases were acute trauma [21]. In one study, 17 cases were not reported in these terms [18]. The interventions mainly included three parts: radical debridement, antibiotic treatment, and Ilizarov methods, which included only the bone transport technique. The Ilizarov method for the treatment of CSBD of the tibia generally involves bifocal or trifocal osteosynthesis. A bone defect longer than 6 cm was an indicator of trifocal transport [17]. There were 507 (507/619) patients that received bifocal bone transport technique, 43 patients received trifocal bone transport technique, and for the remaining patients, there was no clear data. Further details are listed in Tables 1 and 2.

The mean age at the time of injury was 36.1 years (range 13–89), and most patients were men (496 men, 100 women and for 23 cases the gender was not specified) [13–39] (Table 1). The mean delay from injury to Ilizarov bone transport treatment was 11.6 months (range 1–62); this value was not reported in 11 stu-
dies. The patients had an average of 3.44 (range 1–35) previous surgical procedures before receiving treat-
ment by the Ilizarov method; 11 studies did not report this information [13–39]. The mean delay from injury

Table 1 Descriptive characteristics of component studies

| Author/s               | Published year | Study design | Treatment period | Number of patients | Mean age (range) | Male/female ratio | Follow-up rate (%) | Mean follow-up time (range) (months) |
|------------------------|----------------|--------------|------------------|--------------------|------------------|-------------------|-------------------|-----------------------------------|
| Madhusudhan et al.     | 2008           | PC           | 3 years          | 22                 | 37.2 (20–52)     | 18/4              | 100               | 13 (6–20)                        |
| Pirwani et al.         | 2008           | RS           | 2004–2006        | 16                 | 32 (20–60)       | 16/0              | 100               | 16 (12–27)                       |
| Bumbasirevic et al.    | 2010           | RS           | 1991–1996        | 30                 | 30.4 (20–48)     | 29/1              | 100               | 99 (62–122)                      |
| Megas et al.           | 2010           | RS           | 1998–2005        | 9                  | 39.7 (21–75)     | 7/2               | 100               | 26.6 (16–42)                     |
| Lin et al.             | 2012           | RS           | 1997–2012        | 16                 | 36 (18–70)       | nr                | 93.7              | nr                               |
| Babar et al.           | 2013           | PC           | 2009–2011        | 17                 | 32.7 (18–52)     | 15/2              | 100               | nr                               |
| Feng et al.            | 2013           | RS           | nr               | 21                 | 34.6 (19–49)     | 15/6              | 90.4              | 31 (12–72)                       |
| Krappinger et al.      | 2013           | PC           | 2004–2009        | 15                 | 32 (16–61)       | 11/4              | 100               | 17.3 (nr)                        |
| Selim                  | 2013           | RC           | 2010–2011        | 10                 | 30 (22–40)       | 10/0              | 100               | 28.8 (24–36)                     |
| Shadid et al.          | 2013           | RC           | 2009–2010        | 12                 | 43.4 (28–89)     | 10/2              | 100               | 14.25 (nr)                       |
| Spiegl et al.          | 2013           | PC           | 2006–2009        | 25                 | 46 (20–60)       | 22/3              | 100               | 29.4 (25–38)                     |
| Xu et al.              | 2013           | RS           | 2003–2011        | 30                 | 34.1 (19–49)     | 21/9              | 100               | 29 (12–72)                       |
| Yin et al.             | 2014           | RS           | 2004–2011        | 66                 | 37.0 (nr)        | 62/4              | 90                | 25.91 (18–46)                    |
| Morsy                 | 2014           | PC           | 2010–2013        | 12                 | 36.5 (24–48)     | 10/2              | 100               | 9.2 (6–20)                       |
| Marais et al.          | 2014           | RC           | 2009–2013        | 7                  | 29 (28–44)       | nr                | 85.7              | 28 (nr)                         |
| Azzam et al.           | 2015           | RS           | 2011–2013        | 30                 | 32 (18–52)       | 30/0              | 100               | 18 (10–32)                       |
| Bernstein et al.       | 2015           | RC           | 2006–2012        | 30                 | 43 (25–56)       | 24/6              | 100               | 31 (nr)                         |
| Khan et al.            | 2015           | RS           | 2005–2010        | 24                 | 38 (13–74)       | 21/3              | 100               | 11 (8–46)                       |
| Peng et al.            | 2015           | RS           | 2008–2011        | 58                 | 29 (18–51)       | 38/20             | 100               | 31 (24–63)                       |
| Wani et al.            | 2015           | RS           | 2010–2012        | 26                 | 39 (20–65)       | 22/4              | 100               | nr                               |
| Aboumira et al.        | 2016           | RC           | 1999–2001        | 25                 | 44.5 (21–75)     | 19/6              | 100               | 53 (25–74)                       |
| Aktuglu et al.         | 2016           | RS           | 1995–2013        | 24                 | 35.04 (8–69)     | 21/3              | 100               | 74.08 (39–122)                   |
| Furmetz et al.         | 2016           | RS           | 2000–2010        | 8                  | 39 (27–54)       | 7/1               | 100               | 46 (nr)                         |
| Rohilla et al.         | 2016           | PC           | 2008–2013        | 35                 | 36.1 (12–60)     | 30/5              | 97.5              | 25.4 (6–48)                      |
| Tetsworth et al.       | 2017           | RC           | nr               | 21                 | 38.2 (nr)        | 18/3              | 100               | 25.5 (12–84)                     |
| Yilihamu et al.        | 2017           | RS           | 1996–2015        | 14                 | 35.9             | 11/3              | 100               | 96 (nr)                         |
| Zhang et al.           | 2018           | RS           | 2010–2015        | 16                 | 39.1 (16–65)     | 9/7               | 100               | 29.5 (nr)                       |

nr not reported, PC prospective cohort, RS retrospective study, RC retrospective cohort
to Ilizarov treatment and the mean previous operative procedures were both not reported in the same 9 studies (Table 3).

The mean bone defect was 6.58 cm (range 1.6–20) according to 25 studies; there was no clear information from 2 studies [35, 38] (Table 4). Minimum CSBD was over 3.0 cm in 24 of the studies. Minimum bone defect sizes were 1.6 cm in Bernstein et al., 2.0 cm in Megas et al. and Khan et al., and 2.5 cm in Wani et al. studies.

Mean follow-up rate was 100% in 22 studies but was 93.7% for Lin et al., 90.4% for Feng et al., 90% for Yin et al., 85.7% for Marais et al. and 97.5% for Rohilla et al. [17, 20, 24, 26, 33]. Overall mean follow-up rate was 98.38% (range 87.5–100). When specified in the study, mean follow-up duration was 34.05 months (range 6–122), which was long enough to evaluate clinical and radiological outcomes in most cases [13–39]. Further details are listed in Table 1.

The main disadvantage of the Ilizarov method is the lengthy EFT. The mean EFT was 10.7 months (range 2.5–23.2) for the patients in this review [13–39]. There was no clear information in 1 out of 27 studies about the mean EFT [38]. The mean EFI was 1.74 months/cm (range 0.28–4.2) in the patients [13–39]. The mean EFI was not reported in 4 studies [17–19, 38]. In some studies, EFI (mean 1.36 months/cm, when specified) was used to evaluate bone healing progress, in some studies a healing index (mean 45.57 days/cm, when specified) was used.

Table 2: Interventions and outcomes of included studies

| Author/s          | Technique  | Bone union rate (%) | Bone results (ASAMI, PALEY) (excellent/good/fair/poor) | Functional results (ASAMI, PALEY) (excellent/good/fair/poor) | Complications (per patient) | EFT (months) | EFI (months/cm) |
|-------------------|------------|---------------------|------------------------------------------------------|-------------------------------------------------------------|-----------------------------|--------------|-----------------|
| Madhusudhan et al.| RD/AT/ACL (IEF) | 100 | 5/8/5/4 | 1/4/6/10 | 2.73 (60/22) | 9.3 | 2.33 |
| Pirwani et al.    | RD/AT/BI (IEF) | 100 | nr | nr | 2.3 (2/16) | 16 | 3 |
| Bumbasirevic et al.| RD/AT/BI (IEF) | 96.6 | 19/10/0/1 | 13/14/2/1 | 1.4 (42/30) | 9.7 | 1.48 |
| Megas et al.      | RD/AT/CO or ACL (IEF) | 100 | 5/4/0/0 | 3/4/2/0 | 1.89 (17/9) | 7.83 | 1.07 |
| Lin et al.        | RD/AT/BI (IEF) | 93.7 | nr | nr | 1 (16/16) | 4.5 | nr |
| Babar et al.      | RD/AT/BI (IEF) | 97 | 13/2/2/0 | 10/4/2/1 | 1 (17/17) | 6 | nr |
| Feng et al.       | RD/AT/BI (IEF) | 100 | 19/2/0/0 | nr | 0.4 (8/21) | 9.8 | 1.48 |
| Krappinger et al. | RD/AT/BI (IEF) | 80 | 7/6/2/0 | 6/7/2/0 | 3 (45/15) | 13.2 | nr |
| Selim             | RD/AT/BI (IEF) | 80 | 7/3/0/0 | 7/3/0/0 | 0.7 (7/10) | 2.5 | 0.28 |
| Shadid et al.     | RD/AT/ACL (IEF) | 100 | 10/2/0/0 | 6/4/2/0 | 0.25 (3/12) | nr | nr |
| Spiegl et al.     | RD/AT/BI (IEF) | 96 | nr | nr | 1.36 (34/25) | 23.2 | 1.9 |
| Xu et al.         | RD/AT/BI (IEF) | 100 | 28/2/0/0 | nr | 0.27 (8/30) | 10 | 1.36 |
| Yin et al.        | RD/AT/BI (IEF) | 100 | 44/15/5/2 | 24/26/10/0 | 1.1 (73/66) | 9.4 | 1.38 |
| Morsy             | RD/AT/BI (IEF) | 100 | 8/3/0/1 | 7/4/1/0 | 1.58 (19/12) | 6.8 | 1.52 |
| Marais et al.     | RD/AT/BI (IEF) | 100 | nr | nr | 1.57 (11/7) | 17.7 | 2.7 |
| Azzam et al.      | RD/AT/BI (IEF) | 100 | 22/6/1/1 | 13/9/7/1 | 1.7 (51/30) | 7.5 | 1.3 |
| Bernstein et al.  | RD/AT/BI (IEF) | 77 | nr | nr | 0.77 (17/22) | 11.03 | 2.5 |
| Khan et al.       | RD/AT/CO or ACL (IEF) | 95.7 | 6/14/1/2 | 8/12/2/1 | 0.5 (12/24) | 8 | 4.2 |
| Peng et al.       | RD/AT/BI (IEF) | 100 | 30/23/5/0 | 28/18/12/0 | 0.67 (39/58) | 10.6 | 1.2 |
| Wani et al.       | RD/AT/BI (IEF) | 100 | 13/9/4/0 | 9/11/5/1 | 2.1 (52/26) | 14.07 | 1.3 |
| Aboumira et al.   | RD/AT/BI (IEF) | 89 | 11/8/3/3 | 11/9/2/3 | 0.72 (18/25) | 11.8 | 2.1 |
| Aktuglu et al.    | RD/AT/BI (IEF) | 95.8 | 12/8/2/2 | 14/9/1/0 | 1 (24/24) | 11.52 | 1.38 |
| Furmetz et al.    | RD/AT/BI (IEF) | 100 | nr | nr | nr | 9.52 | 1.47 |
| Rohilla et al.    | RD/AT/BI (IEF) | 94 | 19/13/0/3 | 14/19/1/1 | 1.2 (42/35) | 11.9 | 1.8 |
| Tetsworth et al.  | RD/AT/BI or ACL (IEF) | 100 | 15/5/1/0 | 14/6/1/0 | 3.1 (nr) | 12.5 | 1.8 |
| Yilihamu et al.   | RD/AT/BI (IEF) | nr | nr | nr | 1.46 (21/14) | 9.8 | 1.51 |
| Zhang et al.      | RD/AT/BI (IEF) | 100 | 10/0/0/6 | 12/4/0/0 | 1.18 (19/16) | 12 | 1.1 |

nr not reported, ACL acute compression and lengthening, ASAMI, PALEY Association for the Study of the Method of Ilizarov, AT antibiotics treatment, BT bone transport, CO compression osteosynthesis, EFI external fixation index, EFT external fixation time, IEF Ilizarov external fixator, RD radical debridement

* 1 patient lost in follow-up

** 6 patients lost in follow-up

*** 1 patient died from liver disease

The mean bone defect was 6.58 cm (range 1.6–20) according to 25 studies; there was no clear information from 2 studies [35, 38] (Table 4). Minimum CSBD was over 3.0 cm in 24 of the studies. Minimum bone defect sizes were 1.6 cm in Bernstein et al., 2.0 cm in Megas et al. and Khan et al., and 2.5 cm in Wani et al. studies.

Mean follow-up rate was 100% in 22 studies but was 93.7% for Lin et al., 90.4% for Feng et al., 90% for Yin et al., 85.7% for Marais et al. and 97.5% for Rohilla et al. [17, 20, 24, 26, 33]. Overall mean follow-up rate was 98.38% (range 87.5–100). When specified in the study, mean follow-up duration was 34.05 months (range 6–122), which was long enough to evaluate clinical and radiological outcomes in most cases [13–39]. Further details are listed in Table 1.

The mean disadvantage of the Ilizarov method is the lengthy EFT. The mean EFT was 10.7 months (range 2.5–23.2) for the patients in this review [13–39]. There was no clear information in 1 out of 27 studies about the mean EFT [38]. The mean EFI was 1.74 months/cm (range 0.28–4.2) in the patients [13–39]. The mean EFI was not reported in 4 studies [17–19, 38]. In some studies, EFI (mean 1.36 months/cm, when specified) was used to evaluate bone healing progress, in some studies a healing index (mean 45.57 days/cm, when specified) was used.
The mean bone union rate was 100% for 15 studies and not reported in one study. It was 95.8% for the remaining 11 studies [13–39]; in 26 studies mean bone union was 90.2% (range 77–100). In these studies, 242 cases had bone union without any problems at the docking site with the external fixator, without any bone grafting. In 193 cases bone grafting at the docking site was routinely performed in all patients immediately after finishing transport. In only 15 cases was early freshening of fracture ends and removal of interposing soft tissue at the docking site performed to achieve union. In the remaining 202 cases, late grafting because of nonunion, plating and intramedullary nailing were performed, and there is not enough information to determine what has been done. Consolidation at the docking site and at the regenerated bone occurred in 49 (89%) of 55 cases after the first procedure [29]. Bone grafting at the docking site is frequently necessary after bone transport is complete. Also, delayed union of the docking side required iliac crest bone graft. Bone grafting as a routine treatment was recommended in 3 included studies [17, 19, 31].

In this review, when the mean complication per patient was evaluated, it was found that 1 out of 27 did not have sufficient information [32] (Table 2). Two of the remaining 26 studies classified complications according to the Paley system. Spiegl et al. found that the average complication rate per patient consists of 0.88 minor and 0.52 major complications [22]. Tetsworth et al. on the other hand, found 1.2 minor and 1.0 major complications [34]. When the remaining studies were reviewed, the mean complications per patient were 1.22 (range 3–60) [13–39].

Spiegl performed bone transport through induced membrane for post-infective tibial defects in excess of 4 cm. His conclusion was that this procedure was futile. Also, there are studies in favor of and opposed to

---

**Table 3** Details of applied treatments

| Author/s            | Mean delay from injury to Ilizarov treatment (range) months | Mean previous operative procedures (range) | Etiology n (%) | Acute trauma | Aseptic lesion | Infected lesion |
|---------------------|------------------------------------------------------------|---------------------------------------------|----------------|--------------|----------------|-----------------|
| Madhusudhan et al.  | 7.8 (nr)                                                   | 3 (2–5)                                     | 0 (0)          | 0 (0)        | 22 (100)       |
| Pirwani et al.      | nr                                                        | nr                                          | 10 (100)       | 0 (0)        | 0 (0)          |
| Bumbasirevic et al. | 8.6 (16–24)                                                | 1.3 (1–3)                                   | 0 (0)          | 0 (0)        | 30 (100)       |
| Megas et al.        | 7.8 (4–14)                                                 | 4.8 (3–6)                                   | 0 (0)          | 0 (0)        | 9 (100)        |
| Lin et al.          | nr                                                        | nr                                          | 0 (0)          | 0 (0)        | 16 (100)       |
| Babar et al.        | nr                                                        | nr                                          | 6 (40)         | 9 (60)       |
| Feng et al.         | 8.6 (6–24)                                                 | 6 (3–14)                                    | 0 (0)          | 0 (0)        | 21 (100)       |
| Krappinger et al.   | 13 (10–41)                                                 | 10.1 (2–35)                                 | 0 (0)          | 0 (0)        | 25 (100)       |
| Selim               | nr                                                        | 10 (100)                                    | 0 (0)          | 0 (0)        |
| Shadid et al.       | 21 (1–62)                                                  | 1.08 (1–2)                                  | 0 (0)          | 0 (0)        | 12 (100)       |
| Spiegl et al.       | 9.5 (1–22.6)                                               | 1 (nr)                                      | 0 (0)          | 0 (0)        | 25 (100)       |
| Xu et al.           | 8.8 (6–24)                                                 | 6 (3–14)                                    | 0 (0)          | 0 (0)        | 30 (100)       |
| Yin et al.          | 22.8 (4–10)                                                | 2.4 (1–8)                                   | 0 (0)          | 0 (0)        | 66 (100)       |
| Morsy               | 18.2 (7–26)                                                | nr                                          | 7 (58)         | 5 (42)       |
| Marais et al.       | 3 (nr)                                                     | nr                                          | 0 (0)          | 7 (100)      |
| Azzam et al.        | nr                                                        | nr                                          | 8 (26.7)       | 22 (73.3)    |
| Bernstein et al.    | nr                                                        | nr                                          | 14 (47)        | 16 (53)      |
| Khan et al.         | 11.9 (1–36)                                                | 2 (nr)                                      | 0 (0)          | 0 (0)        | 24 (100)       |
| Peng et al.         | 7.1 (1.4–11.6)                                             | 6.3 (3–10)                                  | 0 (0)          | 0 (0)        | 58 (100)       |
| Wani et al.         | 8.2 (4.6–28)                                               | 2.5 (1–5)                                   | 0 (0)          | 0 (0)        | 26 (100)       |
| Aboumira et al.     | nr                                                        | nr                                          | 7 (28)         | 18 (72)      |
| Aktuglu et al.      | nr                                                        | 3.64 (0–11)                                 | 8 (33.3)       | 16 (66.6)    |
| Füretnitz et al.    | nr                                                        | nr                                          | 7 (87.5)       | 1 (12.5)     |
| Rohilla et al.      | 5.8 (0.9–22.8)                                             | 1.22 (nr)                                   | 0 (0)          | 35 (100)     |
| Tetsworth et al.    | nr                                                        | 4.5 (nr)                                    | 0 (0)          | 0 (0)        | 21 (100)       |
| Yilihamu et al.     | nr                                                        | nr                                          | 0 (0)          | 14 (100)     |
| Zhang et al.        | 16.9 (3–45)                                                | 4.25 (nr)                                   | 0 (0)          | 0 (0)        | 16 (100)       |

*nr not reported*
antibiotic cement spacer application [26, 37]. There is not enough clear information on this. Radical debridement is the most important step for eradicating infection of bone and soft tissue.

The most common complications with Ilizarov fixators were PTI and joint stiffness; details are in Table 5. Superficial PTI and/or joint stiffness were seen in 410 cases out of 619. When the studies were evaluated according to the frequency of PTI, 3 studies out of 27 had 100% PTI [1, 2, 25] and 2 studies had no information about PTI [17, 32]. Mean PTI frequency in the studies was 9 (range 1–40). In two studies dated 2008, it was reported that PTI was seen in all cases [13, 14]. The percentage of this frequency was 46.6% (range 10–100). Out of 595 patients who were evaluated in the studies, with regard to information on PTI, 299 had PTI. PTI was especially reported as the most commonly seen complication [19, 22, 24, 25, 28, 30, 33, 37].

For 128 patients in 23 studies, ankle or joint stiffness was reported. But there was no clear distinction reported and the mean percentage was 25% (range 0–100). In some studies, equinus deformity was noted under a separate column. In the 4 studies where there was no mention of joint stiffness, equinus deformity was reported [22, 27, 29, 39]. Of the 27 studies, 22 reported equinus deformity. Mean equinus deformity was 12% (range 0–100) when the cases were evaluated according to ankle and knee joint problems in 23 studies; at the end of the treatment, 95 cases had ankle contracture and/or equinus deformity, 46 cases had knee joint stiffness and 20 cases had both knee and ankle contracture on the same side. Some ankle stiffness or equinus deformities were related to treatment, while some were due to a

Table 4 Further details of applied treatment

| Author/s          | Bone defect Incidence (%) | Mean size (range) (cm) | Mean latency period (range) (days) | Type of Ilizarov treatment (n, %) |
|-------------------|---------------------------|------------------------|-----------------------------------|----------------------------------|
|                    |                           |                        |                                   | Bifocal Trifocal Bifocal or trifocal |
| Madhusudhan et al.| 100                       | 4 (2–11)               | nr (5–7)                          | 22 (100) 0 (0) 0 (0)              |
| Pirwani et al.    | 100                       | 4.5 (2–8)              | nr                                | 16 (100) 0 (0) 0 (0)              |
| Bumbasirevic et al.| 100                      | 6.9 (4–11)             | 7                                 | 30 (100) 0 (0) 0 (0)              |
| Megas et al.      | 100                       | 5 (2–12)               | nr (3–5)                          | 6 (66.6) 0 (0) 3 (33.3)           |
| Lin et al.        | 100                       | 8 (4–12)               | 7                                 | 8 (50) 8 (50) 0 (0)               |
| Babar et al.      | 100                       | 5.8 (nr)               | 7                                 | 17 (100) 0 (0) 0 (0)              |
| Feng et al.       | 100                       | 6.6 (3–12)             | 7                                 | 21 (100) 0 (0) 0 (0)              |
| Krappinger et al. | 100                       | 6.6 (3–14.7)           | nr (10–14)                        | 15 (100) 0 (0) 0 (0)              |
| Selim             | 100                       | 9 (6–12)               | 7                                 | 0 (0) 10 (100) 0 (0)              |
| Shadid et al.     | nr                        | nr                     | nr                                | 0 (0) 0 (0) 12 (100)              |
| Spiegl et al.     | 100                       | 5.3 (3–13)             | 7                                 | 25 (100) 0 (0) 0 (0)              |
| Xu et al.         | 100                       | 6.4 (3–12)             | 7                                 | 0 (0) 0 (0) 30 (100)              |
| Yin et al.        | 100                       | 6.27 (3–13)            | nr (7–10)                         | 66 (100) 0 (0) 0 (0)              |
| Morsy             | 100                       | 4.6 (4–7)              | nr (7–10)                         | 12 (100) 0 (0) 0 (0)              |
| Marais et al.     | 100                       | 7 (5–8)                | 7                                 | 7 (100) 0 (0) 0 (0)               |
| Azzam et al.      | 100                       | 7.4 (3–12)             | 7                                 | 30 (100) 0 (0) 0 (0)              |
| Bernstein et al.  | 100                       | 5.9 (1.6–13)           | nr                                | 30 (100) 0 (0) 0 (0)              |
| Khan et al.       | 100                       | 3.2 (2–5)              | nr                                | 8 (33.3) 0 (0) 16 (66.6)          |
| Peng et al.       | 100                       | 9.2 (6–15)             | 10 (nr)                           | 58 (100) 0 (0) 0 (0)              |
| Wani et al.       | 100                       | 5.1 (3–8)              | 7                                 | 18 (75) 0 (0) 8 (25)              |
| Aboumira et al.   | 100                       | 6.5 (3–17)             | nr (12–14)                        | 16 (64) 9 (36) 0 (0)              |
| Aktuglu et al.    | 100                       | 7.01 (5–18)            | nr (5–7)                          | 24 (100) 0 (0) 0 (0)              |
| Fürmetz et al.    | 100                       | 9 (3.1–13.4)           | 7                                 | 8 (100) 0 (0) 0 (0)               |
| Rohilla et al.    | 100                       | 7.27 (6–12)            | 7                                 | 35 (100) 0 (0) 0 (0)              |
| Tetsworth et al.  | 100                       | 7 (3–10)               | nr                                | 21 (100) 0 (0) 0 (0)              |
| Yilihamu et al.   | 100                       | nr (> 3)               | 10                                | 14 (100) 0 (0) 0 (0)              |
| Zhang et al.      | 100                       | 10.9 (6–20)            | nr (7–10)                         | 0 (0) 16 (100) 0 (0)              |

nr not reported
| Author/s          | Number of patients | Pin tract infection (n) | Wire breakage (n) | Refracture (n) | Joint stiffness (n) | Amputations (n) | Equinus deformity (n) | Docking site problems (n) | Malunion (angular deformity) (n) | Persistent infection (n) | Regeneration problems (n) | Others                                           |
|------------------|-------------------|------------------------|------------------|----------------|-------------------|----------------|------------------------|----------------------------|----------------------------|------------------------|-------------------------|----------------------------------|
| Madhusudhan et al. | 22                | 22                     | 7                | nr             | 22                | 0              | 22                     | nr                        | nr                        | 6                      | 1                       | 2 knee septic arthritis 22 limb oedema |
| Pirwani et al.    | 16                | 16                     | 0                | nr             | 0                 | 0              | 0                      | 2                         | 0                         | 2                      | 1                       | nr                                |
| Bumbasirevic et al. | 30               | 14                     | 0                | 0              | 16                | 0              | 19                     | 4                         | nr                        | nr                     | nr                      | 1 peroneal neuritis 2 chronic pain 4 limb oedema |
| Megas et al.      | 9                 | 8                      | 0                | nr             | 5                 | 0              | nr                     | 0                         | 2                         | 0                      | 0                       | nr                                |
| Lin et al.        | 16                | nr                     | nr               | nr             | nr                | nr             | nr                     | 0                         | 0                         | 1                      | nr                      | nr                                |
| Babare et al.     | 17                | 8                      | 3                | nr             | nr                | nr             | nr                     | 1                         | nr                        | 0                      | 1                       | nr                                |
| Fenget et al.     | 21                | 3                      | nr               | nr             | 0                 | 0              | nr                     | 2                         | nr                        | 0                      | nr                      | nr                                |
| Krappinger et al. | 15                | 9                      | nr               | nr             | 5                 | 0              | 3                      | 8                         | 2                         | 2                      | nr                      | nr                                |
| Selim             | 10                | 1                      | 0                | 1              | 3                 | 0              | 2                      | 2                         | 0                         | 0                      | 0                       | nr                                |
| Shadd et al.      | 12                | 2                      | 1                | 0              | 0                 | 0              | nr                     | 0                         | nr                        | 0                      | nr                      | nr                                |
| Spiegl et al.     | 25                | 9                      | 0                | nr             | 0                 | 1              | 1                      | 5                         | 5                         | 7                      | 0                       | nr                                |
| Xu et al.         | 30                | 3                      | 1                | nr             | 0                 | 0              | nr                     | 2                         | 0                         | 0                      | 1                       | early mineralization                |
| Yin et al.        | 66                | 40                     | 4                | 2              | nr                | 0              | nr                     | 6                         | 0                         | 0                      | nr                      | nr                                |
| Morsy             | 12                | 12                     | 0                | nr             | 1                 | 0              | 1                      | 1                         | 1                         | 1                      | 3                       | nr                                |
| Maras et al.      | 7                 | 2                      | 0                | 1              | 1                 | 1              | 1                      | 2                         | 0                         | 0                      | 0                       | 2 flap dehiscence 1 residual length discrepancy 1 skin invagination |
| Azzam et al.      | 30                | nr                     | 1                | 1              | 14                | 0              | 0                      | 1                         | 4                         | 1                      | 1                       | 1 residual length discrepancy 1 skin invagination 1 skin invagination |
| Bernstein et al.  | 30                | 5                      | 0                | 3              | 0                 | 0              | 3                      | 1                         | 3                         | nr                     | 0                       | 1 knee septic arthritis 2 skin entrapment |
| Khan et al.       | 24                | 5                      | 0                | nr             | 0                 | 1              | 1                      | 0                         | 1                         | 1                      | 0                       | 2 skin entrapment                |
| Peng et al.       | 58                | 18                     | 1                | 0              | 5                 | 0              | 1                      | 0                         | 0                         | 0                      | 0                       | 0                                |
| Wani et al.       | 26                | 23                     | 0                | nr             | 8                 | 0              | 3                      | 9                         | 0                         | 1                      | 2                       | 2 residual length discrepancy |
| Aboumira et al.   | 25                | 14                     | 3                | 2              | 0                 | 0              | 1                      | 2                         | 1                         | 2                      | 4                       | nr                                |
| Aktuglu et al.    | 24                | 17                     | 0                | nr             | 7                 | 0              | 3                      | 5                         | 0                         | 0                      | 0                       | 6 residual length discrepancy |
| Furmetz et al.    | 8                 | nr                     | nr               | nr             | nr                | nr             | nr                     | nr                        | nr                        | nr                     | nr                      | nr                                |
| Rohilla et al.    | 35                | 25                     | 2                | 1              | 25                | 1              | 0                      | 0                         | 8                         | 0                      | 0                       | nr                                |
| Author/s          | Number of patients | Pin tract infection (n) | Wire breakage (n) | Refracture (n) | Joint stiffness (n) | Amputations (n) | Equinus deformity (n) | Docking site problems (n) | Malunion (angular deformity) (n) | Persistent infection (n) | Regeneration problems (n) | Others                        |
|------------------|--------------------|------------------------|-------------------|----------------|---------------------|------------------|-----------------------|-----------------------------|-----------------------------|---------------------------|---------------------------|----------------------------|
| Tetsworth et al. | 21                 | 8                      | 1                 | 1              | 5                   | 0                | 1                     | 7                          | 0                          | nr                        | 9                         | nr                        |
| Yilihamu et al.  | 14                 | 5                      | 0                 | nr             | 8                   | 0                | 2                     | 4                          | 0                          | 0                         | 0                        | 2 knee dislocation, 1 ankle dislocation |
| Zhang et al.     | 16                 | 13                     | 3                 | 1              | 3                   | 0                | 3                     | 0                          | nr                         | 1                         | nr                       |                            |

nr not reported
previous injury or treatment: the causes were not clear-cut. Spiegel et al. reported 5 patients (20%) who required upper ankle arthrodesis as a sequel of posttraumatic or infectious arthritis, but they were not directly related to Ilizarov procedures [22]. Megas et al. also observed stiffness of the ankle joint in 55% of patients and reported it as a common and severe residual problem after such surgical intervention [16]. Ankle problems are the most important source of residual disability after successful use of the Ilizarov device for the treatment of tibial bone defects. Though knee stiffness was largely overcome with physiotherapy, foot and ankle stiffness persisted and worsened despite bony union. This accounts for the poor outcome in the results. Only Tetsworth et al. reported 3 transient ankle stiffness and 2 transient knee flexion contractures [34]. Poor results are not correlated with ankle and knee joint problems and this shows that the majority of these problems are transient.

When the studies were evaluated according to the healing problems seen at the docking site, there was no information in 4 studies [20, 23, 34, 38]. In 3 studies, fracture healing was achieved without bone grafting at the docking site [13, 16, 30]. In the remaining 20 studies, ABG grafting was performed in 100% of cases for 6 studies. There were 151 cases evaluated in these 6 studies. In 23 studies there were a total of 525 cases, with grafts used in 211 of them, the majority of the grafts being ABG grafts. A total of 36.38% of the cases evaluated in the studies had bone grafting at the docking site. The mean percentage of patients who had docking site grafting was 40.1% (range 3.3–100). Docking site healing problems are summarized in Table 6.

When the studies were evaluated according to regeneration site, there was no information about this in 5 studies [15, 17, 20, 24, 32]. Generally, in the other studies, there was not enough detailed information about the regeneration site. Refracture at the docking site or the regeneration site, after the circular external fixator was removed (between 1 month and 1 year), was seen in a total of 13 (3.82%) cases [21, 24, 26, 31, 33, 34, 36, 39]. Three of these 13 cases happened after tri-focal bone transport and this requires attention [36]. Amputation is one of the risks of infected bone defects and the Ilizarov method can minimize this potential outcome. In this study 6 (1%) of the cases treated with Ilizarov resulted in amputation [22, 26, 27, 32, 33]. These are considered as “failure” in the results. Complications are summarized in Table 5.

When infected CSBD cases were taken into consideration, there were 18 studies available. In this group the mean bone defect size was not reported in two studies [16, 18], in the remaining 16 studies the mean bone defect size was 6.6 cm (range 1.6–20); the number of the mean previous surgical procedures was 3.62 cm (range 1–35), previous surgical procedures were not reported in 11 studies. The mean EFT was 10 months (range 4.5–23.2) and it was not reported in one study. The mean EFI was 1.48 (range 0.52–4.2) and it was not reported in 3 studies. Mean complication rate per patient was 1.22 (range 0.25–3.1). Bone results were excellent in 242 (62%), good in 109 (27.9%), fair in 21 (5.3%) and poor in 18 (4.6%) cases. These results belong to 13 studies and in 5 studies this was not reported. Functional results were excellent in 146 (44%), good in 128 (38.6%), fair in 44 (13.2%) and poor in 13 (3.9%). Eradication of infection and bone union were achieved in almost every patient. Only Spigel et al. reported recurrent infection in seven cases (28%) [22].

The criteria recommended by ASAMI were adopted to evaluate bone results and functional results in the studies. Sometimes, clinical efficacy was assessed using Paley’s grading system and patient satisfaction at the last follow-up [15, 16, 19–21, 23, 29, 37]. Bone results were evaluated in 20 studies by ASAMI criteria with data of 502 patients. The information on the remaining 7 studies was not clear [14, 17, 20, 22, 26, 32, 35]. The bone results were excellent, good, fair and poor in 303 (60.4%), 143 (28.5%), 34 (6.4%) and 25 (5%) patients respectively. The functional results were obtained from 18 studies with 444 patients. The functional results were excellent, good, fair and poor in 200 (45%), 167 (37.6%), 58 (13%) and 19 (4.3%) respectively. The excellent and good rate in bone results and functional results were 88.9% and 82.3%, respectively. Detailed information on bone and functional outcomes are listed in Table 2.

Discussion

Bone transport can be done through many devices like ring/circular fixators, monolateral fixators or intramedullary nail systems. Each device has its own advantages and disadvantages. Ilizarov fixators have been in use for many years, but very few studies in the literature have focused on outcomes of ring fixators in infected or noninfected CSBD of tibia treated with distraction osteogenesis.

In the literature, only 3 meta-analyses and systematic reviews analyze the effectiveness, complications, and clinical results of Ilizarov methods in the treatment of long bone defects of the tibia. One of these was made by Papakostidis et al. in 2013 [40]. In this study, 37 reports from between 1989 and 2012 were evaluated. Unfortunately, this study took tibial and femoral bone defects together into consideration. Twenty-three of 37 studies evaluated tibial bone defects in 518 cases. The only significant difference that could be established was a fourfold decrease of the likelihood of fair functional results in the tibia subgroup compared with the femur subgroup [40].
The most important message of this study was that the authors noticed a 3.7 times increase in the odds of refracture when the size of the tibial defect exceeded 8 cm.

The second systematic review of tibia infected nonunion treated by the Ilizarov method was made by Yin et al. [24], by reviewing literature from PubMed, Cochrane Library, EMBASE and other relevant English orthopedic journals between January 1995 and April 2013. The initial literature search identified 225 relevant records, and finally 16 studies and a total of 303 patients were included in the systematic review [24]. The following data were calculated: the mean age was 34.4 years (range 25–44); the mean size of bone defects was 6.01 cm (range 3.5–10.7); the mean follow-up was 44.37 months (range 13–99); the bone union rate was 90.2% (range 77–100%); the good and excellent rate in bone results was 87.5% (range 45–100%); the good and excellent rate in functional results was 76% (range 23–97%); the mean number of complications per patient was 1.47 (range 0.12–3.35); the mean EFT was 9.1 months (range 3.1–13.9); and the mean EFI was 1.46 months/cm (range 0.55–2.33).

The third study made by Yin et al. [41] was a systematic review and meta-analysis of Ilizarov methods in the treatment of infected nonunion of tibia and femur. Unfortunately, this also took infected tibias and femurs together into consideration. A comprehensive literature search was performed using SCI, PubMed, Cochrane Library, and EMBASE between January 1995 and August 2015. A total 590 patients with infected nonunion of tibia and femur treated by Ilizarov methods from 24 studies were included in this review [41]. For patients with infected nonunion, the mean age was 34 years and the mean previous number of surgical procedures was 3.84. The mean bone defect length was 6.54 cm and the mean length of follow-up was 32 months. Bone grafting as a routine treatment was recommended in 1 included study. The average bone union rate was 97% in the studies. The mean number of complications for every patient was 1.22, the mean EFT was

| Author/s          | Ilizarov cases (n) | Bone grafting n (%) | Graft type       | Approach                  |
|-------------------|--------------------|---------------------|------------------|---------------------------|
| Madhusudhan et al.| 22                 | 0                   | nr               | Ilizarov                  |
| Pirwani et al.    | 16                 | 2 (12.5)            | nr               | Ilizarov                  |
| Bumbasirevic et al.| 30                | 1 (3.3)             | ABG              | Ilizarov                  |
| Megas et al.      | 9                  | 0                   | 0                | Ilizarov                  |
| Lin et al.        | 16                 | 16 (100)            | ABG              | IMN                       |
| Babar et al.      | 17                 | 4 (23.5)            | ABG              | Ilizarov (accordion)      |
| Feng et al.       | 21                 | nr                  | nr               | Ilizarov                  |
| Krappinge et al.  | 15                 | 15 (100)            | nr               | Ilizarov                  |
| Selim             | 10                 | 2 (20)              | ABG              | Ilizarov                  |
| Shadid et al.     | 12                 | nr                  | nr               | Ilizarov                  |
| Spiegl et al.     | 25                 | 25 (100)            | ABG, BMP         | Plate/screw               |
| Xu et al.         | 30                 | nr                  | nr               | Ilizarov                  |
| Yin et al.        | 66                 | 6 (9)               | ABG              | Ilizarov                  |
| Morsy             | 12                 | 4 (25)              | ABG              | Ilizarov                  |
| Marais et al.     | 7                  | 7 (100)             | ABG              | Ilizarov                  |
| Azzam et al.      | 30                 | 30 (100)            | ABG              | Ilizarov                  |
| Bernstein et al.  | 22                 | nr                  | nr               | Ilizarov                  |
| Khan et al.       | 24                 | 0                   | 0                | Ilizarov                  |
| Peng et al.       | 58                 | 58 (100)            | ABG              | Ilizarov                  |
| Wani et al.       | 26                 | 3 (11.5)            | ABG              | Ilizarov                  |
| Aboumira et al.   | 25                 | 9 (36)              | ABG              | Ilizarov                  |
| Aktuglu et al.    | 24                 | 0                   | 0                | IMN                       |
| Furmetz et al.    | 8                  | 7 (75)              | ABG              | Plate/Iizarov             |
| Rohilla et al.    | 35                 | 15 (42.8)           | ABG              | Ilizarov                  |
| Tetsworth et al.  | 21                 | nr                  | nr               | Ilizarov                  |
| Yilhamu et al.    | 14                 | 4 (28.5)            | ABG              | Ilizarov                  |
| Zhang et al.      | 16                 | 3 (18.7)            | nr               | Ilizarov                  |

nr not reported, ABG autologous bone graft, BMP bone morphogenetic protein, IMN intramedullary nail
9.41 months, and the mean EFI was 1.64 months/cm. Bone results were evaluated in 16 studies by ASAMI. Functional results were reported in 16 studies. The poor rate for bone results and functional results were 8% and 10%, respectively [41].

The rates of refracture and amputation were both 4% in the review by Yin et al. [41], which is similar to the 5% and 2.9%, respectively, reported by Papakostidis et al. [40]. The rates of malunion, infection recurrence, and knee stiffness were, respectively, 7%, 5%, and 12%. Pin-track infection is the most common complication in using Ilizarov methods, and significant statistical heterogeneity was found for the complication. The rate of pin-track infection was 10–100% among included studies in our systematic review. The poor rate in bone results and functional results were 7% and 9%. The rates of bone grafting, knee stiffness, malunion, refracture, infection recurrence, and amputation were, respectively, 7%, 4%, 6%, 13%, 4% and 13%, respectively [41].

Our study was a review of 10 years of data. Papakostidis et al. studied a period of 23 years. Yin et al. performed two separate studies. The first one spanned 18 years and the second one 20 years [24, 40, 41]. Tibia and femur bone defects were taken together in the study by Papakostidis et al., and tibia and femur nonunions were taken together in the second study by Yin et al. When all four studies, including ours, were evaluated, the mean ages of the patients were 34, 34, 34, and 36, respectively. The ratio of bone union for Yin et al.’s first study, which only included tibias, was 96% and for ours it was 90%. But when we looked at excellent and good bone rates, it was 87.5% for Yin et al.’s review and 88.8% in our review. The mean EFT was 9.19 months in Yin et al.’s first study and 10.75 months in our review. The mean EFI was 1.74 months/cm. The mean bone defect length was 6.01 cm in Yin et al.’s study and 6.58 cm in our review. Complications per patient had its lowest rate in our series, at 1.22%. Also, the rate of amputation was lowest in our review, at 1%. The recurrent infection rate was 4.58% in our study: it was at its lowest. The refracture rate was 4% and it was very close to other studies in our review. In our series, malunion was high, at 8.4%; this value was 5.7% for Papakostidis et al., was not reported in Yin et al.’s first study, and was 7% for their second study. PTI was 50.25% in our study but this value was not reported in the other three studies. Details are in Table 7.

To the best of our knowledge, this is the first narrative review of infected and noninfected critical-sized

| Table 7 Comparison of reviews |
|-------------------------------|
| Papakostidis et al. | Yin et al. | Yin et al. | Our study |
| **Characteristics** | | | |
| Study period | 1989–2012 | 1995–2013 | 1995–2015 | 2008–2018 |
| Number of evaluated studies | 37 | 16 | 24 | 27 |
| Number of patients | 898 | 303 | 590 | 619 |
| Long bone involved | Tibia + femur | Tibia | Tibia + femur | Tibia |
| Study types | 1 PC, 1P, 1 R, 34 RC | nr | 1 PC, 22 R, 1 RC | 6 PC, 15 R, 6 RC |
| Mean age (range) | 34.85 | 34.44 (25–44) | 34.11 (nr) | 36.1 (13–89) |
| Mean follow-up (range) (months) | 43.81 | 44.37 (13–99) | 32.49 (nr) | 34.05 (6–122) |
| Mean bone union rate (range) (%) | 94.3 (92–96.6) | 96.69 (87–100) | 97.26 (nr) | 90.24 (77–100) |
| Bone results excellent+good (%) | nr | 87.52 | 88.76 | 88.8 |
| Functional results excellent+good (%) | nr | 76 | 76.70 | 82.6 |
| EFT (months) | nr | 9.19 | 9.41 | 10.75 |
| EFI (months/cm) | nr | 1.46 | 1.64 | 1.74 |
| Mean previous operative procedures (range) | 3.46 | nr | 3.84 | 3.44 |
| Infection etiology (%) | 60.61 | 100 | 97.26 | 88.8 |
| Mean bone defect (range) (cm) | 7.37 | 6.01 (3.5–10.7) | 6.54 (nr) | 6.58 (1.6–20) |
| **Complications** | | | |
| Complications (per patient) | nr | 1.47 | 1.23 | 1.22 |
| Refracture (%) | 5 | nr | 4 | 4 |
| Amputation (%) | 2.9 | nr | 4 | 1 |
| Malunion (%) | 5.7 | nr | 7 | 8.41 |
| Recurrent Infection (%) | nr | nr | 5 | 4.58 |
| Pin tract infection (%) | nr | nr | nr | 46.6 |

nr not reported, PC prospective cohort, P prospective, RC retrospective cohort, R retrospective
tibial bone defects treated by Ilizarov methods. We were able to provide a large number of data on characteristics of patients and treatment results through 27 included studies.

In conclusion, our review and the current evidence suggest that Ilizarov methods in the treatment of infected or noninfected CSBD resulted in satisfactory effects in bone results and functional results. Radical debridement is the key step in controlling bone infection. However, our review lacks a direct comparison with any other treatment options, and further randomized controlled trials are needed to draw more valuable conclusions. Some studies have declared bone transport using the Ilizarov method for CSBD is the gold standard [32, 36]. The results obtained from this review support this opinion. The most important problem of the classic Ilizarov method is the long duration of the treatment period. Also, PTI, compliance of the patient and the discomfort of the external fixator are other problems that come with this treatment type. Among the modifications made in order to shorten the healing time at the docking site are grafting of the area, and plate and nail application at the site. In order to avoid circular external fixator problems, monolateral fixator usage and bone transport with intramedullary nailing are being used. Although many modifications have been suggested, one of the biggest series consists of classic/traditional applications.

But there are some difficulties in obtaining results from current studies involving traditional Ilizarov methods. The reason for this may be that the authors, when evaluating the cases, did not use homogenous criteria, and did not document the patients in detail. For example, this is very obvious when one looks at regeneration sites in the studies. In the Tables, it can be seen that many items are marked as “not reported”. If the authors use more homogenous criteria for patients, the reporting will be more accurate. Secondly, when evaluating the Ilizarov bone transport method, some studies took femur and tibia together into consideration, and it was impossible to separate the two. These studies were excluded from the review. The information pertaining to these patients has been lost. Another problem is that when comparing the classic/traditional Ilizarov method with any other method in small series, the information was not clear enough, and that made an accurate evaluation hard. A more accurate evaluation could be obtained through more homogenous series.

**Abbreviations**

- CFTBD: critical-sized tibial bone defects
- DO: distraction osteogenesis
- ABG: autologous bone graft
- IM: Ilizarov method
- IMN: Intramedullary nail
- EFI: external fixation index
- EFT: external fixation time
- PTI: pin tract infection
- CSTBD: critical-sized tibial bone defects
- PTI: pin tract infection
- EF: external fixation

**Authors' contributions**

AV performed the literature search and chose the reports to be taken into account. KE prepared the Tables. KA analyzed the data and derived the results. All authors read and approved the final manuscript.

**Acknowledgements**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Availability of data and materials**

The datasets supporting the conclusions of this article are included within the article.

**Consent for publication**

Not applicable.

**Ethics approval and consent to participate**

Not applicable.

**Funding**

Not applicable.

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 11 February 2019 Accepted: 20 March 2019

Published online: 16 April 2019

**References**

1. Tong K, Zhong Z, Peng Y, Lin C, Cao S, Yang Y, Wang G (2017) Masquelet technique versus Ilizarov bone transport for reconstruction of lower extremity bone defects following posttraumatic osteomyelitis. Injury 48(7):1616–1622
2. Haines NM, Lack WD, Seymour RB, Bosse MJ (2016) Defining the lower limit of a “critical bone defect” in open diaphyseal tibial fractures. J Orthop Trauma 30(5):e156–e163
3. Keating JF, Simpson AH, Robinson CM (2005) The management of fractures with bone loss. J Bone Joint Surg. 87:142–150
4. Ilizarov GA (1989) The tension-stress effect on the genesis and growth of tissues. Part I. The influence of stability of fixation and soft-tissue preservation. Clin Orthop Relat Res 249:249–281
5. Ilizarov GA (1989) The tension-stress effect on the genesis and growth of tissues: part II. The influence of the rate and frequency of distraction. Clin Orthop Relat Res 47:263–285
6. Ilizarov GA (1990) Clinical application of the tension-stress effect for limb shortening. Clin Orthop Relat Res 250:8–26
7. Hamdy RC, Rendon JS, Tabrizian M (2012) Distraction osteogenesis and its challenges in bone regeneration. Int. J. Bone Regeneration, pp 185–212
8. Paley D, Maar DC (2000) Ilizarov bone transport treatment for tibial defects. J Orthop Trauma 14(2):76–85
9. Paley D, Catagni MA, Argnani F, Villa A, Benedetti GB, Cattaneo R (1989) Ilizarov treatment of tibial nonunions with bone loss. Clin Orthop Relat Res 241:146–165
10. Catagni MA, Guerreschi F, Lovisetti L (2011) Distraction osteogenesis for bone repair in the 21st century: lessons learned. Injury 42:580–586
11. Cattaneo R, Villa A, Catagni M, Tentori L (1985) Treatment of septic or non-septic diaphyseal pseudoarthroses by Ilizarov’s monofocal compression method. Rev. Chir Orthop Reparatrice Appar Mot 71:223–229
12. Cattaneo R, Catagni M, Johnson EE (1992) The treatment of infected nonunions and segmental defects of the tibia by the methods of Ilizarov. Clin Orthop Relat Res 280:143–152
13. Madhusudhan TR, Ramesh B, Manjunath K, Shah HM, Sundaresh DC, Krishnappa N (2008) Outcomes of Ilizarov ring fixation in recalcitrant...
infected tibial non-unions—a prospective study. J Trauma Manag Outcomes 2(1):6
14. Pirwani MA, Siddiqui MA, Soomro YH (2008) Management of infected non-union tibia by intercalary bone transport. Pak J Surg 24:26–30
15. Bumbasirević M, Tomić S, Lesić A, Milošević I, Atkinson HD (2010) War-related infected tibial nonunion with bone and soft-tissue loss treated with bone transport using the Ilizarov method. Arch Orthop Trauma Surg 130(6):739–749
16. Megas R, Saridis A, Kouzelis A, Kalliovkas A, Mylonas S, Tyllianakis M (2010) The treatment of infected nonunion of the tibia following intramedullary nailing by the Ilizarov method. Injury 41(3):294–299
17. Lin CC, Chen CM, Chiu FY, Su YF, Liu CL, Chen TH (2012) Staged protocol for the treatment of chronic tibial shaft osteomyelitis with Ilizarov’s technique followed by the application of intramedullary locked nail. Orthopedics. 35(12):e1769–e1774
18. Babar IU, Afsar SS, Gulzar M (2013) Treatment of segmental tibial bone loss by distraction osteogenesis. J Postgrad Med Inst 27(1):78–82
19. Krappinger D, Irenberger A, Zegg M (2013) Treatment of large post-traumatic tibial bone defects using the Ilizarov method: a subjective outcome assessment. Arch Orthop Trauma Surg 133(6):789–795
20. Feng ZH, Yuan Z, Jun LZ, Tao Z, Fa ZY, Long MX (2013) Ilizarov method with bone segment extension for treating large defects of the tibia caused by infected nonunion. J Orthop Surg (Hong Kong). 23(1):52–55
21. Selim NM (2013) Ilizarov trifocal lengthening followed by intramedullary nailing for massive posttraumatic tibial bone defects. Acta Orthop Belg 79(6):706–710
22. Spiegl U, Patzold R, Friederichs J, Hungerer S, Militz M, Buhren V (2013) Clinical course, complication rate and outcome of segmental resection and distraction osteogenesis after chronic tibial osteitis. Injury 44(8):1049–1056
23. Xu K, Fu X, Li YM, Wang CG, Li ZJ (2014) A treatment for large defects of the tibia caused by infected nonunion: Ilizarov method with bone segment extension. Ir J Med Sci 183(3):423–428
24. Yin P, Zhang Q, Mao Z et al. (2014) The treatment of infected tibial nonunion by bone transport using the Ilizarov external fixator and a systematic review of infected nonunion treated by Ilizarov methods. Acta Orthop Belg 80(6):426–435
25. Morsy MA (2014) Unifocal bone transport in tibial nonunion using Ilizarov fixator. Al-Azhar Asiat Med J 12(2):107–103
26. Marais LC, Ferreira N (2015) Bone transport through an induced membrane in the management of tibial bone defects resulting from chronic osteomyelitis. Strategies Trauma Limb Reconstr. 10(1):27–33
27. Khan MS, Rashid H, Umer M, Qadir I, Hafeez K, Iqbal A (2015) Salvage of infected non-union of the tibia with an Ilizarov ring fixator. J Orthop Surg (Hong Kong). 23(1):52–55
28. Wani N, Baba A, Kangoo K, Mir M (2011) Role of early Ilizarov ring fixator in definitive management of type II, IIIA and IIIB open tibial shaft fractures. Int Orthop 35(6):915–923
29. Abuomrta IE, Sala F, Elbatrawy Y, Lovisetti G, Alati S, Capitanii D (2016) Distraction osteogenesis for tibial nonunion with bone loss using combined Ilizarov and Taylor spatial frames versus a conventional circular frame. Strateg Trauma Limb Reconstr. 11(3):153–159
30. Aktuglu K, Guñay H, Alakbarov J (2016) Monofocal bone transport technique for bone defects greater than 5 cm in tibia: our experience in a case series of 24 patients. Injury. 47(6):540–546
31. Azzam W, Atef A (2016) Our experience in the management of segmental bone defects caused by gunshot. Int Orthop 40(2):233–238
32. Fürmetz J, Soo C, Behrendt W, Thaller PH, Siekmann H, Bohme J, Josten C (2016) Bone transport for limb reconstruction following severe tibial fractures. Orthop Rev. 8(1):6384
33. Rohilla R, Siwach K, Devgan A, Singh R, Wadhwani J, Naseem A (2016) Outcome of distraction osteogenesis by ring fixator in infected, large bone defects of tibia. J Clin Orthop Trauma 7(Suppl 2):201–209
34. Tetsworth K, Paley D, Sen C, Jaffe M, Maar DC, Glatt V, Hohmann E, Herzenberg JE (2017) Bone transport versus acute shortening for the management of infected tibial non-unions with bone defects. Injury 48(10):2276–2284
35. Yihiamu Y, Keremu A, Afula A, Maimaiti X, Ren P, Yusuuf A (2017) Outcomes of post-traumatic tibial osteomyelitis treated with an Orthofix LRS versus an Ilizarov external fixator. Injury 48(7):1636–1643
36. Zhang Y, Wang Y, Di J, Peng A (2018) Double-level bone transport for large post-traumatic tibial bone defects: a single centre experience of sixteen cases. Int Orthop 42:1157–1164
37. Peng J, Min L, Xiang Z, Huang F, Tu C, Zhang H (2015) Ilizarov bone transport combined with antibiotic cement spacer for infected tibial non-union. Int J Clin Exp Med 8(6):10058–10065
38. Shahid M, Hussain A, Bridgeman P, Bose D (2013) Clinical outcomes of the Ilizarov method after an infected tibial non union. Arch Trauma Res. 2(2):71–75
39. Bernstein M, Fragomen AT, Sabharwal S, Barclay J, Rozbruch SR (2015) Does integrated fixation provide benefit in the reconstruction of post-traumatic tibial bone defects? Clin Orthop Relat Res 473(10):3143–3153
40. Papakostidis C, Bhandar M, Giannoudis PV (2013) Distraction osteogenesis in the treatment of long bone defects of the lower limbs: effectiveness, complications and clinical results, a systematic review and meta-analysis. Bone Joint J 95(12):1673–1780